Protocol Ledger

NCT05948943 · Phase II/III · RECRUITING

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Interventional Phase II/III clinical trial protocol NCT05948943 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-24 Enrollment: 232 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05948943
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)232 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05948943
Protocol FieldVerified Registry Value
NCT IdentifierNCT05948943
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment232 participants (ESTIMATED)
Registered Start Date2023-11-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05948943
Hospital Research SiteLocationSite Profile
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
University of North Carolina at Chapel HillChapel Hill, NCOpen Hospital Dossier ->
Cleveland ClinicCleveland, OHOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI